Mendus AB (CHIX:IMMUS) Change In Receivables: kr16.93 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IMMUS Mendus AB CHIX:IMMUS
28 GF Score
Price kr32.70
! 2 Warning Signs
View Full Analysis

What is Mendus AB Change In Receivables?

Mendus AB CHIX:IMMUS 28 Change In Receivables is kr16.93 Mil as of Mar. 2026. GuruFocus rates CHIX:IMMUS with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Mendus AB's change in receivables for the quarter that ended in Mar. 2026 was kr2.15 Mil. It means Mendus AB's Accounts Receivable declined by kr2.15 Mil from Dec. 2025 to Mar. 2026 .

Mendus AB's change in receivables for the fiscal year that ended in Dec. 2025 was kr22.67 Mil. It means Mendus AB's Accounts Receivable declined by kr22.67 Mil from Dec. 2024 to Dec. 2025 .

Mendus AB's Accounts Receivable for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Mendus AB's liquidation value for the three months ended in Mar. 2026 was kr5.10 Mil.

Mendus AB  (CHIX:IMMUs) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Mendus AB's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Mendus AB's accounts receivable are only considered to be worth 75% of book value:

Mendus AB's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=74.128-69.027+0.75 * 0+0.5 * 0
=5.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mendus AB Change In Receivables Related Terms

Mendus AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for Mendus AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mendus AB Change In Receivables Chart

Mendus AB Annual Data
Trend Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.36 23.47 -64.38 38.11 22.67

Mendus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.89 -1.11 0.78 15.11 2.15
CHIX:IMMUS
28GF Score
Mendus AB CHIX:IMMUS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mendus AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr16.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of kr16.93 Mil mean?
Mendus AB (CHIX:IMMUS) has a Change In Receivables of kr16.93 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Mendus AB and its competitors.
Is Mendus AB's Change In Receivables too high?
Mendus AB's current Change In Receivables is kr16.93 Mil. Overall, Mendus AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Mendus AB's Change In Receivables compare to VRTX and REGN?
Mendus AB's Change In Receivables of kr16.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Mendus AB and its competitors. Mendus AB's current Change In Receivables is kr16.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mendus AB stock overvalued right now?
Mendus AB (CHIX:IMMUS) has a current Change In Receivables of kr16.93 Mil. The current Change In Receivables is kr16.93 Mil. Mendus AB's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Mendus AB (CHIX:IMMUS), the current Change In Receivables is kr16.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mendus AB Business Description

Other Exchanges IMMU:Sweden1YG0:Germany
Address Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
28GF Score

Get the complete analysis for CHIX:IMMUS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr32.70
Price